DPP4 inhibitor (Vildagliptin) and its effect on Glucose levels and Arterial stiffness in patients with Type II Diabetes Mellitus

Trial Profile

DPP4 inhibitor (Vildagliptin) and its effect on Glucose levels and Arterial stiffness in patients with Type II Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2016 New trial record
    • 29 Sep 2016 Results presented at the 26th Scientific Meeting of the International Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top